EXAS

EXAS

USD

Exact Sciences Corporation Common Stock

$69.590-0.480 (-0.685%)

Reaalajas hind

Healthcare
Diagnostics & Research
Ameerika Ühendriigid

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$70.070

Kõrge

$72.810

Madal

$67.970

Maht

1.54M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

13.2B

Tööstusharu

Diagnostics & Research

Riik

United States

Kauplemisstatistika

Keskmine maht

2.95M

Börs

NCM

Valuuta

USD

52 nädala vahemik

Madal $38.81Praegune $69.590Kõrge $72.83

Seotud uudised

Analyst Upgrades

TD Cowen Maintains Buy on Exact Sciences, Raises Price Target to $90

TD Cowen analyst Dan Brennan maintains Exact Sciences with a Buy and raises the price target from $74 to $90.

Vaata rohkem
TD Cowen Maintains Buy on Exact Sciences, Raises Price Target to $90
Analyst Upgrades

Baird Maintains Outperform on Exact Sciences, Raises Price Target to $88

Baird analyst Catherine Schulte maintains Exact Sciences with a Outperform and raises the price target from $72 to $88.

Vaata rohkem
Baird Maintains Outperform on Exact Sciences, Raises Price Target to $88
Analyst Upgrades

Benchmark Maintains Buy on Exact Sciences, Raises Price Target to $75

Benchmark analyst Bruce D. Jackson maintains Exact Sciences with a Buy and raises the price target from $60 to $75.

Vaata rohkem
Benchmark Maintains Buy on Exact Sciences, Raises Price Target to $75
Analyst Upgrades

Guggenheim Maintains Buy on Exact Sciences, Raises Price Target to $75

Guggenheim analyst Subbu Nambi maintains Exact Sciences with a Buy and raises the price target from $70 to $75.

Vaata rohkem
Guggenheim Maintains Buy on Exact Sciences, Raises Price Target to $75
Analyst Upgrades

Barclays Maintains Overweight on Exact Sciences, Raises Price Target to $77

Barclays analyst Luke Sergott maintains Exact Sciences with a Overweight and raises the price target from $65 to $77.

Vaata rohkem
Barclays Maintains Overweight on Exact Sciences, Raises Price Target to $77
Analyst Upgrades

Stifel Maintains Buy on Exact Sciences, Raises Price Target to $80

Stifel analyst Daniel Arias maintains Exact Sciences with a Buy and raises the price target from $67 to $80.

BusinessWire

Exact Sciences to Participate in November Investor Conference

Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate